September 8, 2021 -- Mission Bio has improved its Tapestri platform to expand its accessibility and utility in hematologic oncology (heme-onc) research.
The updates allow researchers to apply single-cell analysis to a wider range of projects due to new ready-to-use panels, Tapestri single-cell DNA published panels, and a lowered input threshold. Researchers now can access single-cell insights from as few as 20,000 cells while conserving samples.
BioLegend's expanded TotalSeq D antibodies catalog has also been added to Tapestri. The addition enables researchers to start with a predesigned heme-onc panel (or customize one to fit the needs of a specific project) and connect genomic data to a broader array of phenotypes, according to the firm.
Mission Bio is hosting a virtual launch event of its platform on September 21, 2021, at 8 a.m. Pacific time.
Copyright © 2021 scienceboard.net
Member Rewards
Earn points for contributing to market research. Redeem your points for merchandise, travel, or even to help your favorite charity.
Research Topics
Interact with an engaged, global community of your peers who come together to discuss their work and opportunities.
Conferences
Connect
